Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$1.74 +5.5%	$1.86	$1.21 ▼ $3.81	$42.97M	0.68	261,100 shs	70,989 shs
EGRX Eagle Pharmaceuticals	$3.19	$3.19	$1.50 ▼ $3.87	$41.43M	0.83	6,795 shs	1 shs
MDNA Medicenna Therapeutics		$0.29	$0.15 ▼ $0.84	$10.93M	1.3	160,047 shs	1.27 million shs
NNVC NanoViricides	$1.44 +5.1%	$1.50	$0.94 ▼ $2.07	$23.14M	0.96	242,025 shs	109,767 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	+5.45%	+8.75%	-13.43%	-1.14%	+12.26%
EGRX Eagle Pharmaceuticals	0.00%	-0.31%	-13.55%	+59.50%	-25.99%
MDNA Medicenna Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
NNVC NanoViricides	0.00%	-4.00%	-15.79%	-19.55%	-28.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AADI Aadi Bioscience	0.4384 of 5 stars	1.0	0.0	0.0	0.0	2.5	1.3
EGRX Eagle Pharmaceuticals	1.7514 of 5 stars	0.0	2.0	3.9	0.0	3.3	0.0
MDNA Medicenna Therapeutics	1.4203 of 5 stars	3.5	0.0	0.0	0.6	1.7	0.0
NNVC NanoViricides	0.7239 of 5 stars	0.0	5.0	0.0	2.5	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	2.00	Hold	$1.75	0.57% Upside
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
MDNA Medicenna Therapeutics	3.00	Buy	$2.50	∞ Upside
NNVC NanoViricides	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	1.71	N/A	N/A	$4.29 per share	0.41
EGRX Eagle Pharmaceuticals	$257.55M	0.16	$7.98 per share	0.40	N/A	∞
MDNA Medicenna Therapeutics	N/A	N/A	N/A	N/A	$0.32 per share	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	$0.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	11/4/2025 (Estimated)
EGRX Eagle Pharmaceuticals	$35.64M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MDNA Medicenna Therapeutics	-$7.60M	-$0.09	N/A	N/A	N/A	N/A	-42.68%	-35.17%	N/A
NNVC NanoViricides	-$8.29M	-$0.70	N/A	∞	N/A	N/A	-87.90%	-78.69%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MDNA Medicenna Therapeutics	N/A	N/A	N/A	N/A	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
MDNA Medicenna Therapeutics	N/A	9.57	9.57
NNVC NanoViricides	N/A	3.44	2.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
EGRX Eagle Pharmaceuticals	85.36%
MDNA Medicenna Therapeutics	12.38%
NNVC NanoViricides	10.30%

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
EGRX Eagle Pharmaceuticals	28.90%
MDNA Medicenna Therapeutics	33.10%
NNVC NanoViricides	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
MDNA Medicenna Therapeutics	16	69.64 million	46.59 million	Not Optionable
NNVC NanoViricides	20	16.07 million	14.92 million	Optionable

MDNA, AADI, EGRX, and NNVC Headlines

Recent News About These Companies

NanoViricides says antiviral NV-387 may reduce cancer resurgence risk tied to viral infections

August 18, 2025 | proactiveinvestors.com

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

August 18, 2025 | accessnewswire.comA

NanoViricides says antiviral candidate NV-387 could address global measles surge

July 30, 2025 | proactiveinvestors.com

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

July 30, 2025 | accessnewswire.comA

NanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387

July 23, 2025 | proactiveinvestors.com

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

July 23, 2025 | accessnewswire.comA

Measles Now Has a Drug – NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

July 21, 2025 | usatoday.com

NanoViricides says lead antiviral boosted survival in measles-infected mice

July 21, 2025 | proactiveinvestors.com

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

July 21, 2025 | accessnewswire.comA

NanoViricides designs trial protocol for phase II MPox Clade Ia with a novel drug NV-387 for treating MPox disease

July 18, 2025 | pharmabiz.comP

WHO Extended Global Emergency Status of MPox Epidemic – Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

July 16, 2025 | azcentral.comA

NanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergency

July 16, 2025 | proactiveinvestors.com

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

July 16, 2025 | accessnewswire.comA

NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks

July 15, 2025 | proactiveinvestors.com

NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks

July 15, 2025 | proactiveinvestors.com

NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox

July 15, 2025 | finance.yahoo.com

NanoViricides nears completion of clinical trial design for MPox treatment

July 14, 2025 | proactiveinvestors.com

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides

July 14, 2025 | markets.businessinsider.com

NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case

July 7, 2025 | theglobeandmail.com

NanoViricides advances antiviral candidate NV-387 into Phase 2 trials for Mpox

July 2, 2025 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDNA, AADI, EGRX, and NNVC Company Descriptions

Aadi Bioscience NASDAQ:AADI

$1.74 +0.09 (+5.45%)

As of 08/22/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Eagle Pharmaceuticals NASDAQ:EGRX

$3.19 0.00 (0.00%)

As of 08/22/2025

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Medicenna Therapeutics NASDAQ:MDNA

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

NanoViricides NYSE:NNVC

$1.44 +0.07 (+5.11%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.46 +0.02 (+1.67%)

As of 08/22/2025 07:55 PM Eastern

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time